Combination therapy to treat hcv infection in a population of patients infected with HCV HIV

摘要

Claim 1: a compound of the formula (1) or one of its pharmaceutically acceptable salts, where B is the rest of formula (2); lu2070 is lu00b9 is Meo; Br; and Ru00b2 is rest of formula (3), for use in a method for the treatment of hepatitis C viral infection (HCV or alleviate one or var) The symptoms in a patient who was coinfected with human immunodeficiency virus (HIV),This method includes administering to the patient: (a) The Compound of formula (1) or a pharmaceutically acceptable salts thereof; (b) and (c) to interferon and Ribavirin.Claim 28: a packaged Pharmaceutical composition comprising a pack containing: (a) one or more doses of the following formula (1) or one of its pharmaceutically acceptable salts,Where B is the rest of formula (2); lu2070 is lu00b9 is Meo; Br; and Ru00b2 is rest of formula (3); and (b) written instructions relating to the Administration of the compound of formula (1) or one of its pharmaceutically acceptable salts, interferon and Ribavirin for the treatment of infection by HCV in a patient who was coinfected with HIV.